Sciwind Biosciences Co., Ltd has received a significant boost as the National Medical Products Administration (NMPA) has accepted its filing for review of another indication for ecnoglutide. The Chinese biopharmaceutical company is now seeking NMPA’s approval for the use of its drug in long-term weight management for adult patients, complementing a diet and physical activity regimen. This follows the company’s initial bid last month for the drug’s use in type 2 diabetes (T2D).
Ecnoglutide: A Promising GLP-1 Receptor Agonist
Ecnoglutide is a cAMP signaling biased, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has successfully completed three regulatory Phase III studies in China, focusing on T2D and obesity. These studies have demonstrated the drug’s excellent therapeutic effects, along with good safety and tolerability profiles. This scientific validation positions ecnoglutide as a strong candidate for the treatment of both conditions.
Global Expansion with Rights Granted to South Korea’s HK inno.N Corporation
In a strategic move to expand its global footprint, Sciwind granted development and commercialization rights for ecnoglutide to South Korea’s HK inno.N Corporation (KOSDAQ: 195940) in a deal valued at USD 56 million, concluded in May this year. This partnership signifies the potential international reach of Sciwind’s innovative drug and underscores the company’s commitment to improving healthcare outcomes globally.-Fineline Info & Tech
